The potential of RNA methylation in the treatment of cardiovascular diseases

Kai Wang; YuQin Wang; YingHui Li; Bo Fang; Bo Li; Wei Cheng; Kun Wang; SuMin Yang

doi:10.1016/j.isci.2024.110524

The potential of RNA methylation in the treatment of cardiovascular diseases

iScience. 2024 Jul 20;27(8):110524. doi: 10.1016/j.isci.2024.110524. eCollection 2024 Aug 16.

Authors

Kai Wang^{1

2}, YuQin Wang², YingHui Li², Bo Fang², Bo Li², Wei Cheng³, Kun Wang^{1

2}, SuMin Yang¹

Affiliations

¹ Department of Cardiovascular Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
² Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China.
³ Department of Cardiovascular Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.

Abstract

RNA methylation has emerged as a dynamic regulatory mechanism that impacts gene expression and protein synthesis. Among the known RNA methylation modifications, N6-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), 3-methylcytosine (m³C), and N7-methylguanosine (m⁷G) have been studied extensively. In particular, m⁶A is the most abundant RNA modification and has attracted significant attention due to its potential effect on multiple biological processes. Recent studies have demonstrated that RNA methylation plays an important role in the development and progression of cardiovascular disease (CVD). To identify key pathogenic genes of CVD and potential therapeutic targets, we reviewed several common RNA methylation and summarized the research progress of RNA methylation in diverse CVDs, intending to inspire effective treatment strategies.

Keywords: Cardiovascular medicine; Clinical genetics.

Publication types

Review